...
search icon
qcls-img

Q/C Technologies, Inc., Common Stock

QCLS

NAQ

$4.01

+$0.26

(6.93%)

1D

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$7.72M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
437.52K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.24 L
$180 H
$4.01

About Q/C Technologies, Inc., Common Stock

Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York. more

Returns

Data is not properly formatted.

Financials

Dec '21Dec '22Dec '23Dec '24
Total Revenue----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses28.20M15.28M16.36M8.66M[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":54.19,"profit":true},{"date":"2023-12-31","value":58.01,"profit":true},{"date":"2024-12-31","value":30.71,"profit":true}]
Operating Income(28.20M)(15.28M)(16.36M)(8.66M)[{"date":"2021-12-31","value":-2820124700,"profit":false},{"date":"2022-12-31","value":-1528276300,"profit":false},{"date":"2023-12-31","value":-1636021800,"profit":false},{"date":"2024-12-31","value":-866018800,"profit":false}]
Total Non-Operating Income/Expense(1.69M)85.43K12.36M(14.70M)[{"date":"2021-12-31","value":-13.66,"profit":false},{"date":"2022-12-31","value":0.69,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-118.92,"profit":false}]
Pre-Tax Income(29.89M)(15.20M)(4.00M)(23.36M)[{"date":"2021-12-31","value":-2988904500,"profit":false},{"date":"2022-12-31","value":-1519733600,"profit":false},{"date":"2023-12-31","value":-399995000,"profit":false},{"date":"2024-12-31","value":-2335933400,"profit":false}]
Income Taxes----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(29.89M)(15.20M)(4.00M)(23.36M)[{"date":"2021-12-31","value":-2988904500,"profit":false},{"date":"2022-12-31","value":-1519733600,"profit":false},{"date":"2023-12-31","value":-399995000,"profit":false},{"date":"2024-12-31","value":-2335933400,"profit":false}]
Income From Discontinued Operations----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(29.89M)(15.20M)(4.00M)(23.36M)[{"date":"2021-12-31","value":-2988904500,"profit":false},{"date":"2022-12-31","value":-1519733600,"profit":false},{"date":"2023-12-31","value":-399995000,"profit":false},{"date":"2024-12-31","value":-2335933400,"profit":false}]
EPS (Diluted)(3.25K)(1.18K)(564.55)(1.17K)[{"date":"2021-12-31","value":-324656.73,"profit":false},{"date":"2022-12-31","value":-117747.27,"profit":false},{"date":"2023-12-31","value":-56454.92,"profit":false},{"date":"2024-12-31","value":-117255.06,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

QCLS
Current Ratio 0.93

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

QCLS
ROA (LTM) 0.00%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

QCLS
Debt Ratio Lower is generally better. Negative is bad. 0.32
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.68

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

QCLS
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.00
EV/R 0.00
EV/Ebitda NM

FAQs

What is Q/C Technologies, Inc. share price today?

Q/C Technologies, Inc. (QCLS) share price today is $4.01

Can Indians buy Q/C Technologies, Inc. shares?

Yes, Indians can buy shares of Q/C Technologies, Inc. (QCLS) on Vested. To buy Q/C Technologies, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in QCLS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Q/C Technologies, Inc. be purchased?

Yes, you can purchase fractional shares of Q/C Technologies, Inc. (QCLS) via the Vested app. You can start investing in Q/C Technologies, Inc. (QCLS) with a minimum investment of $1.

How to invest in Q/C Technologies, Inc. shares from India?

You can invest in shares of Q/C Technologies, Inc. (QCLS) via Vested in three simple steps:

  • Click on Sign Up or Invest in QCLS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Q/C Technologies, Inc. shares
What is Q/C Technologies, Inc. 52-week high and low stock price?

The 52-week high price of Q/C Technologies, Inc. (QCLS) is $180. The 52-week low price of Q/C Technologies, Inc. (QCLS) is $3.24.

What is Q/C Technologies, Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Q/C Technologies, Inc. (QCLS) is 0.00

What is the Market Cap of Q/C Technologies, Inc.?

The market capitalization of Q/C Technologies, Inc. (QCLS) is $7.72M

What is Q/C Technologies, Inc.’s stock symbol?

The stock symbol (or ticker) of Q/C Technologies, Inc. is QCLS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top